Literature DB >> 35962895

Intensive vs. conventional blood pressure goals in older patients with type 2 diabetes: a systematic review and meta-analysis.

Rene Rodriguez-Gutierrez1,2,3, Andrea Flores-Rodríguez1, Karina Raygoza-Cortez1, Mariana Garcia-Leal1, Sofía Mariño-Velasco1, Hiram H Plata-Huerta1, Melissa Sáenz-Flores1, Luz A Ramirez-Garcia1, Amanda Rojo-Garza1, Spyridoula Maraka2,4,5, Naikky V Singh-Ospina2,6, Juan P Brito2,7, Jose G Gonzalez-Gonzalez8,9,10.   

Abstract

PURPOSE: Assess the effect of intensive vs conventional blood pressure goals on patient-important outcomes in older adults with type 2 diabetes.
METHODS: A comprehensive search was performed using electronic databases. Randomized controlled trials comparing intensive vs conventional blood pressure goals in adults over 60 years of age with type 2 diabetes were included. Events were evaluated using a modified Mantel-Haenszel meta-analysis with Peto's method. Study selection and data extraction were performed independently and in duplicate.
RESULTS: Seven trials were included. A 19% risk reduction (OR 0.81; 95% CI 0.69-0.95; I2 = 8%; p = 0.35) in the occurrence of major adverse cardiovascular events (MACE) and 37% risk reduction (OR 0.63; 95% CI 0.51-0.79; I2 = 0%; p = 0.56) in the occurrence of fatal or non-fatal stroke was documented in the intensive treatment group. There were no differences in the occurrence of all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and peripheral vascular disease. Data regarding treatment adverse effects and microvascular outcomes was scarce.
CONCLUSIONS: Intensive blood pressure goals in older patients with diabetes were associated with a lower risk of stroke and MACE, but not with all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and peripheral vascular disease.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Blood pressure goals; Hypertension; Older adults; Type 2 diabetes

Mesh:

Year:  2022        PMID: 35962895     DOI: 10.1007/s12020-022-03159-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  1 in total

1.  Hispanic representation in diabetes cardiovascular outcomes trials.

Authors:  A Taylor Kelley; Kara Mizokami-Stout; Matthew J O'Brien; Michael E Bowen; Jeremy Sussman
Journal:  BMJ Open Diabetes Res Care       Date:  2019-05-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.